Constellium SE

CSTM

CIK 0001563411 · Quarterly mode · latest period FY2026 (Q1) (ending 2026-03-31) · sourced from SEC EDGAR

At a glance · FY2026 (Q1)

Revenue
$2.46B
↑+24.4% +$482Mvs FY2025 (Q1)
Operating Income
$227M
↑+141.5% +$133Mvs FY2025 (Q1)
Net Income
$199M
↑+437.8% +$162Mvs FY2025 (Q1)
Gross Profit
$420M
↑+59.7% +$157Mvs FY2025 (Q1)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
40/100
  • Profitability
    0Insufficient data
  • Liquidity
    40Current Ratio 1.29 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    100Asset Turnover 1.68x (1.0+ = capital-efficient)
  • Growth
    98Revenue YoY +24.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project CSTM's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 27.9%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$37.36
Total enterprise IV
$5.30B
Diluted shares
0.14B
Terminal PV
$4.12B (78% of total)
Year-5 FCF
$485M
YearProjected FCFDiscounted PV
+1$199M$181M
+2$248M$205M
+3$311M$233M
+4$388M$265M
+5$485M$301M
Terminal$6.63B$4.12B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$333M
investment in PP&E
Stock buybacks (TTM)
$128M
share count reduction

Balance sheet · 2026-03-31

latest filed snapshot
Total assets
$5.84B
everything owned
Total liabilities
$4.71B
everything owed
Stockholders' equity
$1.12B
shareholder claim

Recent performance · 11 quarters

Revenue↑+24.4% +$482M
$2.46B
Net Income↑+437.8% +$162M
$199M
Free Cash Flow↑+109.1% +$12M
$1M

Drill down